KKR, a private equity firm, completed the acquisition of IVI-RMA, a biotechnology company, for $3bn. IVI-RMA is a clinic that specializes in human reproduction, developing reproductive medicine. It was formed in 2017 when a group of doctors and investors from Spain’s eastern region of Valencia merged IVI with US rival RMANJ. The firm manages more than 75 clinics and 28 labs in nine countries.